Technology &
Pipeline
From Biological Insight to
Therapeutic Generation
Most drug development begins with disease.
Sen-Jam begins with the biology beneath it.
Our proprietary Inflammation Atlas maps the inflammatory architecture that shapes resilience and generates combination therapeutics designed for earlier, safer, and more complete inflammatory resolution.
One engine. Multiple programs. Clinically validated.
The Inflammation Atlas:
Mapping Inflammatory Architecture
The Inflammation Atlas is Sen-Jam’s proprietary AI-driven Quantitative Systems Pharmaco-Biology engine, built to model the complex multi-modal inflammatory circuitry that happens upstream of disease.
It maps feedforward inflammatory loops, identifies the molecular nodes that drive them, and predicts combination therapeutics designed to restore balance by working with—not against—the body’s innate immune intelligence, enabling earlier, safer, and more coordinated inflammatory resolution.
Not disease-by-disease discovery. Biology-first therapeutic generation.
Architecture-Level Mapping
Inflammatory loops modeled at the systems level—not isolated targets.
Human-First Data
Built from human inflammatory biology—not animal proxies
Combination Candidate Generation
AI-matched molecules selected for complementary, non-redundant pathway activity.
Biomarker-Linked Validation
Predicted signatures, including NLR, confirmed across two independent Phase 2 datasets.
From Platform to Proof.
Our proprietary Inflammation Atlas was built to identify therapeutic combinations capable of elegantly modulating feed-forward systems to more broadly and safely restore immune balance.
Today, that framework is generating a growing portfolio of resilience-first therapeutics—and has already demonstrated clinical validation across two independent Phase 2 programs. And has generated multiple new combinations across a vast collection of unmet needs.
Different conditions. Shared biology. Measurable outcomes.
SJP-001
Pre-Trigger Resolution
Target Biology
COX-Prostaglandin × Histamine Loop
- 76% reduction in headache severity
- Near-complete symptom resolution
- Superior tolerability versus monotherapy and placebo
- Phase 3 ready
SJP-002C
Therapeutic Resolution
Target Biology
COX-Prostaglandin × Mast Cell × Adaptive Immune Loop
- Selective immune rebalancing observed
- Complete symptom clearance by Day 15
- Cross-program NLR biomarker patent filed
- Expanded therapeutic potential
Translating Biology Into Medicine
A growing portfolio of resilience-first therapeutics—from active development programs to emerging Inflammation Atlas-derived opportunities.
Active Development Assets
Recovery & Performance
- Endurance Athletic Recovery
- Alcohol Hangover Recovery
- Post-Viral Recovery
Respiratory Health
- Upper Respiratory Viral Illness, including COVID
Addiction Medicine
- Polysubstance Use Disorder
Chronic Inflammatory Disease
- Arthritis
Healthy Aging & Metabolic Health
- Inflammaging
- MASH
- Metabolic Recovery
Critical Care
- Inflammatory Rescue Programs
Inflammation Atlas-Derived Programs
Cardiometabolic Health, Neuroinflammation, Fibrosis & Tissue Repair, Chronic Inflammatory Disease, Healthy Aging & Longevity, Additional Undisclosed Programs
Therapeutic Pipeline
Building the Future of Resilience
A growing portfolio of resilience-first therapeutics. A clinically validated discovery platform. A new approach to preserving health before disease emerges.
For partners, investors, and innovators looking beyond today’s therapeutic boundaries.
